MITSUBISHI TANABE PHARMA CORPORATION

The Parkinson's disease market is expected to grow significantly, reaching USD 6.2 billion by 2034, driven by advancements in diagnostics, disease awareness, and emerging therapies. Key therapies in development include ND0612, tavapadon, P2B001, BIIB122/DNL151, Buntanetap, Solengepras, and Minzasolmin. These therapies aim to improve motor function, manage symptoms, and potentially slow disease progression.

Mitsubishi Tanabe Pharma America presents two abstracts on investigational ND0612 for Parkinson's disease at the 2024 Annual Meeting of the Parkinson Study Group. ND0612, a 24-hour continuous subcutaneous infusion of liquid levodopa/carbidopa, is evaluated in the BeyoND study for safety and efficacy over three years, and infusion site reactions.

The toxoplasmosis treatment drugs market is projected to grow from $3.16 billion in 2023 to $4.18 billion by 2028, driven by rising prevalence, product innovations, and increased healthcare expenditure.

Mitsubishi Tanabe Pharma America to present RADICAVA ORS data at 2024 NASP Annual Meeting, focusing on ALS patient demographics, treatment duration, progression milestones, and healthcare resource utilization.

MTPA announces two presentations at the 2024 NASP Annual Meeting on RADICAVA ORS-treated ALS patients, focusing on demographics, treatment duration, progression milestones, and healthcare resource utilization.

MTPA presents RADICAVA ORS data at 2024 NASP Annual Meeting, focusing on ALS patient demographics, treatment duration, progression milestones, and healthcare resource utilization.

ND0612, a continuous levodopa/carbidopa infusion, reduced uncontrolled motor symptoms and improved quality of life in advanced Parkinson’s patients, according to BouNDless and BeyoND studies presented at the 2024 MDS Congress. ND0612 extended daily on time and reduced off time compared to oral levodopa/carbidopa, with gains in motor signs and quality of life, and was generally well-tolerated. The FDA is currently reviewing ND0612 for potential approval.

AI and big data are revolutionizing drug development, significantly reducing costs and time by identifying potential drug targets, optimizing compound selection, and simulating clinical trials, promising more effective medicines for patients.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.